TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02987400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 3 cycles followed by 9 cycles consolidation if not transplant eligible

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 3 cycles followed by 9 cycles consolidation if not transplant eligible
Study: NCT02232633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Study: NCT02808026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5 to 5mg, orally, once daily after breakfast
Study: NCT00879281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action plan
Description: Individualized written Action Plan to enhance self-management and early detection of an exacerbation.
Study: NCT05643365

Intervention type: RADIATION
Intervention: Radioactive Iodine therapy
Description: All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.

Intervention type: RADIATION
Intervention: Radioactive Iodine therapy
Description: All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.

Intervention type: RADIATION
Intervention: Radioactive Iodine therapy
Description: All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
Study: NCT04244279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic workshop
Description: Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Participant will receive a brochure summarizing the main contents of the workshop.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
Study: NCT00252954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levetiracetam
Description: Tablets 2000-3000 mg per day
Study: NCT04210310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
Study: NCT00989391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT03389815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
Study: NCT04588025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care Portable Perfusion Phantom, P4
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care Portable Perfusion Phantom, P4
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Study: NCT00989391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT04401956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bread
Description: Different types of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bread
Description: Different types of bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bread
Description: Different types of bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bread
Description: Different types of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bread
Description: Different types of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bread
Description: Different types of bread
Study: NCT01403545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Curcumin
Description: Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% glucose infusion over 120 minutes
Study: NCT04357509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Super circulating tumor infiltrating lymphocytes(ScTIL)
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion.
Study: NCT02252809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study: NCT00183963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 250mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 500 mg IM
Study: NCT02998047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lintuzumab AC 225
Description: Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
Study: NCT01294462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90 mg, oral dose twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg, oral dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid ASA
Description: Low Dose ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid ASA
Description: Low Dose ASA
Study: NCT00877305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
Study: NCT03421301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary portfolio
Description: The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary portfolio
Description: The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
Study: NCT04210310

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
Study: NCT03993431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-active cement
Description: A cement used for crown cementation, specially recommended for pediatric esthetic crowns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packable glass ionomer
Description: Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
Study: NCT06522048

Intervention type: OTHER
Intervention: Observational studies do not require intervention
Description: This is an observational retrospective study and does not require any intervention.
Study: NCT00144924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy pyloromyotomy
Description: laparoscopic pyloromyotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open pyloromytomy
Description: open pyloromyotomy
Study: NCT02573246

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
Study: NCT02087202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: magnesium sulfate is added to the patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine is added to the patients.
Study: NCT04598126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education manual +traditional physical therapy
Description: Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
Study: NCT02072187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03503292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Rapid metabolizer will receive 1mg IV Granisetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Poor or normal metabolizers will receive 4mg Ondansetron IV
Study: NCT01540409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 (Eteplirsen)
Description: Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
Study: NCT01049802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetititve transcranial magnetic stimulation
Description: 1 Hz rTMS to contralesional hemisphere in patients with stroke

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetititve transcranial magnetic stimulation
Description: 1 Hz rTMS to contralesional hemisphere in patients with stroke
Study: NCT00103519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DITPA (3,5-diiodothyropropionic acid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DITPA (3,5-diiodothyropropionic acid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02228343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Ayurveda includes meditation, yoga, breathing exercises, herbs
Study: NCT01011933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT04420962

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Best corrected visual acuity utilizing the Snellen method

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Best corrected visual acuity utilizing the Snellen method
Study: NCT00043823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 100 mg By Mouth Daily for 3 Weeks
Study: NCT03182595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
Study: NCT03454815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical patency
Description: Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
Study: NCT01873729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Adults with ADHD
Study: NCT05027334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes
Description: Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
Study: NCT01568372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
Study: NCT03609099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg / day once a day oral treatment during 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once a day oral treatment during 3 days.
Study: NCT02726880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: 6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for care
Description: Referral for mental health issues and family support services
Study: NCT02401945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study: NCT03481634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection
Study: NCT00572611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-bilastine
Description: Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
Study: NCT01969617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg, then placebo
Description: One single oral dose Nalmefene on Day 1 and Placebo on Day 8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then Nalmefene 18 mg
Description: One single oral dose Placebo on Day 1 and Nalmefene on Day 8
Study: NCT00246506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
Study: NCT00246506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization
Description: This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
Study: NCT04239794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
Study: NCT03048838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk reduction behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Promotion Intervention
Study: NCT02845778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each sachet contains 0.5 g